



Paris, 29th June 2021

Press Release

Biofutur, a group of medical biology laboratories, has completed an acquisition in the Paris region, backed by its investor Omnes

Biofutur, with the support of its financial investor Omnes, has acquired Laboratoire Bonhoure, a single-site based in Nemours. The acquisition of this site enables Biofutur to strengthen its regional coverage in the south of the Seine-et-Marne area. The newly acquired laboratory, led by Dr Xavier Bonhoure, sees on average 300 patients per day and employs 25 people, and has an annual turnover of over €3 million.

Biofutur is a leading regional laboratory consortium. It possesses 52 sites in the Paris region and has a turnover of more than €100 million. The group is notably involved in the fight against Covid-19 in the region, and manufactures several thousand PCR tests a day via a routine network, as well as at approximately 10 sites dedicated to PCR tests, in coordination with the regional health authority (ARS) and local town authorities.

Christophe Crouzier, Chairman of Biofutur: *“This acquisition fits in perfectly with Biofutur’s strategy, which aims to extend its regional coverage to become a structured mid-cap company.”*

Participants

Omnes, Mid-Cap Buyout & Growth Capital

Benjamin Arm, Managing Partner
Yoann Malys, Director of Investment
Etienne Chemel, Principal
Aubrey Stewart-Quinquis, Analyst

Advisors

Legal structuring: Winston & Strawn (Gilles Bigot and Julie Vern Cesano-Gouffrant, Annie Maudouit-Ridde, Djénéba Samaké)

Financial Advice: Advance Capital (Olivier Poncin, Thibault Fleury)

About Omnes

Omnes is a leading Paris-based European investor in private equity and infrastructure. With €5 billion of assets under management, Omnes provides SMEs with the capital needed to finance growth. The firm has dedicated investment teams across three key areas: Venture Capital, Buyout & Growth Capital and Infrastructure. Omnes is owned by its employees. Omnes is committed to ESG factors and has set up the Omnes Foundation in aid of children’s charities. It is also a signatory to the United Nations Principles for Responsible Investment (PRI). www.omnescapital.com



Press Contact

Aurélien Blanchard-Massoni, aurelie.blanchard-massoni@omnescapital.com - +33 1 80 48 79 52